MURA (Mural Oncology) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Mural Oncology Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Mural Oncology's net issuance of preferred for the three months ended in Dec. 2024 was $0.00 Mil. The number is 0, which means that Mural Oncology has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Mural Oncology's net issuance of preferred for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

Mural Oncology Net Issuance of Preferred Stock Historical Data

The historical data trend for Mural Oncology's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mural Oncology Net Issuance of Preferred Stock Chart

Mural Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Net Issuance of Preferred Stock

Mural Oncology Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Net Issuance of Preferred Stock	Get a 7-Day Free Trial						-	-	-	-	-

Mural Oncology Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Mural Oncology Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Mural Oncology's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Mural Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mural Oncology PLC (NAS:MURA) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380

Website

https://www.muraloncology.com

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.